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Solid lipid nanoparticles (SLNs) are interesting colloidal drug-delivery systems, since they have all 
the advantages of the lipid and polymeric nanoparticles. Freeze-drying is a widely used process for 
improving the stability of SLNs. Cryoprotectants have been used to decrease SLN aggregations during 
freeze-drying. In this study Ampicillin was chosen to be loaded in a cholesterol carrier with nano size 
range. To support the stability of SLNs, freeze-drying was done using mannitol. Particle size, drug 
release profile and antibacterial effects were studied after freeze-drying in comparison with primary 
SLNs. Preparations with 5% mannitol showed the least particle size enlargement. The average particle 
size was 150 and 187 nm before and after freeze-drying, respectively. Freeze-drying did not affect the 
release profile of drug loaded nanopartilces. Also our study showed that lyophilization did not change 
the antimicrobial effect of ampicillin SLNs. DSC analysis showed probability of chemical interaction 
between ampicillin and cholesterol.
Uniterms: Solid lipid nanoparticles. Stability. Cryoprotectant. Freeze-drying. Antibacterial efficacy. 
Particle size
Nanoparticulas lipídicas sólidas (NLSs) são sistemas coloidais de liberação interessantes, uma vez 
que reúnem todas as vantagens de nanopartículas lipídicas e poliméricas. A liofilização é um processo 
amplamente utilizado para melhorar a estabilidade das NLSs e os crioprotetores têm sido usados para 
diminuir a agregação destas durante esse processo. Neste estudo, a ampicilina foi escolhida para ser 
encapsulada em um carreador de colesterol de escala nanométrica. Para manter a estabilidade das NLSs, 
a liofilização foi realizada utilizando-se manitol. O tamanho de partícula, o perfil de liberação do fármaco 
e os efeitos antibacterianos foram estudados após a liofilização em comparação com a NLSs primária. 
De acordo com os resultados, as preparações que contêm 5% de manitol mostraram o menor aumento 
do tamanho de partícula. Os resultados de tamanhos médio foram de 150 e 187 nm antes e depois da 
liofilização, respectivamente. O perfil de liberação prolongada, bem como o efeito antimicrobiano da 
ampicilina NLSs não foram alterados após a liofilização. A análise por DSC evidenciou provável interação 
entre a ampicilina e o colesterol.
Unitermos: Nanopartícula lipídica sólida. Estabilidade. Crioprotetor. Liofilização. Eficiênca 
antibacteriana. Tamanho de particular
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INTRODUCTION
Solid lipid nanoparticles (SLNs) as colloidal carrier 
systems have the advantages of traditional systems but 
avoid some of their major disadvantages (Mehnert, 
Mader, 2001; Hu et al, 2004). Some advantages of 
SLNs are possibility of the incorporation of lipophilic 
and hydrophilic drugs, possibility of controlling drug 
release and drug targeting, increased drug stability, 
high drug payload, lack of biotoxicity of the carrier, 
no problems with respect to large-scale production, 
sterilization possibility, and good tolerability (Zhang 
et al., 2006; Varshosazs et al., 2010; Mukherjee et al, 
2009). The enhancement of antibacterial efficacy of 
antibiotics using SLNs as a carrier was reported as one 
of the advantages of these colloidal systems (Varshosaz 
et al., 2010; Alihoseyni et al., 2014). Freeze-drying has 
been considered as a good technique to improve the 
long-term stability of colloidal nanoparticles. Other 
studies show that poor stability in an aqueous medium is 
a major barrier against the clinical use of nanoparticles 
(Abdelwahed et al., 2006). Also freeze-drying may 
generate many stresses that could destabilize colloidal 
suspension of nanoparticles before turning them to dried 
particles (Abdelwahed et al., 2006). Cryoprotectants 
have been used to decrease SLN aggregations due to 
the stress during the process of freeze-drying (Subedi, 
Kang, Choi, 2009). Glucose, sucrose, trehalose, 
lactose, mannitol, sorbitol, aerosol, maltose, polyvinyl 
pyrrolidone, fructose, dextran, glycerol, polyvinyl 
alcohol, glycine, hydroxypropyl-β-cyclodextrin and 
gelatin were used as cryoprotectant in several studies 
(Mehnert, Mader, 2001; Ghaffari et al., 2011). In this 
study we studied the effect of mannitol in different 
percentages as cryoprtecant in freeze-drying process 
on particle size, morphology, drug release profile and 
antibacterial efficacy of ampicillin SLNs. Our goal was 
to prepare freeze-dried ampicillin SLNs and optimize 
lyophilization process to have minimum impact on their 
physicochemical and antimicrobial properties.
MATERIAL AND METHODS
Material
Cholesterol (Merck, Germany) was used as lipid 
material of SLNs. Tween 80 (Merck) was used as 
surfactant. Ampicillin (Kosar Pharmaceutical Co., Tehran, 
Iran) was used as the active pharmaceutical ingredient. 
Ethanol and acetone (Merck Chemical Company, 
Germany) were organic solvents.
Preparation of ampicillin SLNs
At first 350 mg of cholesterol was added to the mixture 
of acetone and ethanol in ratio of 1 to 3, then the mixture 
was heated in a water bath at 75 °C. Ampicillin was added to 
deionized water containing 1% (w/w) tween 80 as surfactant 
(Varshosaz et al., 2010; Alihoseyni et al., 2014). After that, 
the hot oily phase was added to water at room temperature 
under homogenizing at 11,000 rpm, using IKA® (Staufen, 
Germany) T-18 basic, Ultra-Turrax® (Germany) for 
20 minutes. The prepared mixture was sonicated at 45-50 °C 
for 7 minutes, using a bath-sonicator system (Tecna 6; 
Tecno-Gaz, Sala Baganza, Italy). SLNs were made when the 
mixture temperature was decreased to room temperature. 
The particle size of the nanoparticles was measured by 
a Zetasizer (ZEN3600; Malvern Instruments, Britain). 
Determination of ampicillin 
The spectrophotometric scan of ampicillin was done 
on 200-400 nm wavelength, the maximum absorption was 
seen on 208 nm, the linearity of the results was studied for 
solutions with different concentration (25-200 ppm) in 
buffer and water and R2 of the method were respectively 
0.993 and 0.995. 
Drug loading efficiency
For determination of drug loading efficiency, the 
samples were centrifuged at 26,000 rpm for 45 minutes, at 
4 °C by using a Sigma Laboratories centrifuge (Osterode am 
Harz, Germany). The drug concentration in the supernatant 
was analyzed using spectrophotometer (Shimadzu, Japan) 
at 208 nm and the drug-loading efficiency was calculated 
by using the following equation. (Kimberly, Tabrizian 2005; 
Ghaffari et al. 2012; Alihoseyni et al. 2014) The results 
reported as mean of three analyses with standard deviation. 
Freeze-drying
The particles were freeze-dried using freeze-dryer 
(Lyotrap/Plus, UK) at −80 °C under 0.4 bar. Different 
amounts of mannitol (5,10 and 15%) was used as 
cryoprotectant. 
Morphology study
Morphology of the nanoparticles was characterized 
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by scanning electron microscopy (SEM) before and 
after freeze-drying. The nanoparticles were mounted on 
aluminum stubs, sputter-coated with a thin layer of Au/Pd, 
and examined by using an SEM (Philips XL30, Almelo, 
Netherlands) instrument.
Release studies
Release study was done using the dialysis sack 
method by DO405 Dialysis tubing 23x15 mm (Sigma, 
Germany). Five mL of the formulation before and after 
freeze-drying was placed in dialysis membrane (10-12 
KD) immersed in 50 mL phosphate buffer solution (pH 7.4) 
at room temperature (25±2 oC). The freeze dried particles 
were diluted in 5 mL of deionized water before placing in 
dialysis membrane. The free drug which was not loaded 
on SLNs was removed using centrifuge at 26,000 rpm for 
45 minutes, at 4 °C by a Sigma Laboratories centrifuge. 
One mL samples were withdrawn in predetermined time 
intervals and drug concentration was analyzed using UV 
spectrophotometry (Shimadzu, Japan) method at 208 nm. 
(Varshosaz et al., 2010, Alihoseyni et al, 2014).
DSC analysis
DSC thermograms were obtained using: DSC 823e 
Mettler, Swiss. A certain amount of dried nanoparticle 
powder was crimped in a standard aluminum pan and 
heated from 25–400 °C at a heating rate of 10 °C /min 
under constant purging of nitrogen.
Antimicrobial activity of SLNs
The antimicrobial activity of nanoparticles before 
and after freeze-drying was studied using well diffusion 
test. P. aeruginosa (ATCC 27853) and E. coli (ATCC 
25922) were used as gram negative pathogenic strains. 
The bacterial suspensions with a cell density equivalent 
to 0.5 McFarland (1.5 × 108 CFU/mL) were transferred 
individually onto the surface of Muller–Hinton agar 
plates using sterile swabs. Wells with 8 mm diameters 
were prepared by punching and removing the agar to form 
a well. Aliquots of 100 μL of each original SLNs after 
preparation and SLNs after freeze-drying, were delivered 
into the wells as the test samples. After incubation time for 
48 hours, at 35 °C–37 °C, the zones of inhibition around 
the wells were measured in mm using a caliper. 
RESULTS AND DISCUSSION
Particle size
The evaluation of particles using Malvern zeta 
sizer (ZEN3600) showed a normal distribution of particle 
size before and after freeze-drying when the percentage 
of cryoprotectant was equal to 5%. Results showed that 
more than 70% of particles were smaller than 95 nm in 
size also 85% and 96% of prepared particles were smaller 
than 150 and 285 nm before freeze-drying. More than 
77% of particles were smaller than 69.7 nm, more than 
92% of particles were smaller than 95.3 nm, more than 
98% and 99% were smaller than 130 and 208 nm, after 
lyophilization. Figure 1 shows the particle size distribution 
profile after freeze-drying. This result confirmed that 
lyophilization of ampicillin SLNs did not show any effect 
on particle size of prepared particles. Comparison of 
particle size of SLNs after lyophilization, shows that 5% 
mannitol as cryoprotectant yileds the smallest particles. 
FIGURE 1 - Particle size distribution of ampicillin solid lipid nanoparticles after freeze-drying using 5% mannitol as cryoprotectant.
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The average particle size was 187, 911 and 1930 nm 
for formulations with 5, 10 and 15% mannitol. So the 
lyophilized particles with 5% mannitol were chosen 
to continue the studies. Varshosaz et al. showed that 
sucrose as cryoprotectant in concentration of 12% would 
be suitable choice to avoid particle size increase during 
freeze-drying process of SLNs.
SEM study
Figures 2a and 2b show the morphologies of the 
freeze-dried formulations in comparison with non-
lyophilized particles respectively. Results showed that 
no significant enlargement of particle size was happened 
after freeze-drying. 
Drug loading efficacy
Our results showed 77±4% drug loading efficacy. 
The percentage of drug loading was used for calculations 
of drug release profile as well.
Drug release studies
Figure 3 compares the release profile of ampicillin 
from SLNs before and after lyophilization which lasts 
for about 24 h and releases about 98% of ampicillin 
during this period by a sustained behavior. No significant 
difference was observed between two profiles. No burst 
effect was established for lyophilized SLNs. Varshosaz 
et al. (2012), reported burst effect after freeze-drying of 
amikacin SLNs.
Antimicrobial activities
The antimicrobial activity of lyophilized SLNs of 
ampicillin after redispersion in water is shown in Figure 4a 
and 4b against P. aeruginosa and E. coli. Results showed 
that ampicillin loaded nanoparticles increase antibacterial 
efficacy of ampicillin in comparison with free drug. 
Therefore, lyophilization process did not have impact on 
antimicrobial activity of SLNs as carrier of ampicillin. 
Enhanced antibacterial properties of drug loaded SLNs 
was reported by Ghaffari et al. (2011) before.
DSC analysis
Differential Scanning Calorimetry thermograms 
(DSC) for pure cholesterol, ampicillin and ampicillin-
loaded SLNs were shown in Figure 5. The endotherm 
of melting point of cholesterol has shifted from 132 oC 
to about 166 oC in the SLNs of ampicillin. The melting 
temperature of ampicillin is also seen in 112 oC and 137 oC 
in the thermogram of pure ampicillin. However, the 
melting point of the drug has been covered in the SLNs and 
only the endotherm of probable shifted melting point of 
cholesterol is observable. Sustained release of ampicillin 
from SLNs can be related to probable hydrogen bond 
formation between cholesterol and ampicillin which can 
be seen in DSC thermograms. 
FIGURE 2 - Scanning electron microscopy pictures of ampicillin 
solid lipid nanoparticles after freeze-drying (a), before freeze-
drying in primary preparation (b).
FIGURE 3 - Release profile of ampicillin solid lipid nanoparticles 
before and after freeze-drying.
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FIGURE 4 - Photographs of the zone of inhibition produced by 
free ampicillin and its SLNs in freeze-dried SLNs against P. 
aeruginosa(a) and E. coli (b).
FIGURE 5 - DSC thermograms of raw materials and freeze-dried 
SLNs of ampicillin.
proper croprotectant to have minimum impact on their 
physicochemical and antimicrobial properties. Mannitol 
5%provided the optimum condition to avoid particle 
aggregation. Release profile, DSC analysis, SEM of 
lyophilized SLNs and antibacterial efficacy were studied 
and the results showed no burst effect on release profile 
of ampicillin without significant increase in drug release 
rate. DSC analysis showed probable interaction between 
ampicillin and cholesterol. The SEM photographs 
showed spherical shape of the freeze-dried particles. 
As the final conclusion, freezing of SLNs of ampicillin 
dispersion at -80°C and the addition of 5% mannitol 
before lyophilization inhibited the aggregation of the 
nanoparticles after reconstitution.
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